API Holdings clears all debt while retaining control of Thyrocare

API Holdings, the parent company of health-tech platforms PharmEasy and Thyrocare, announced on Monday that it has successfully repaid its entire outstanding debt of Rs 1,050 crore, becoming debt-free after a multi-year period marked by losses, leverage concerns, and repeated scrutiny over its path to profitability. The company executed the debt repayment through a combination of proceeds from a partial stake sale in its diagnostics subsidiary Thyrocare, alongside internal accruals, according to a statement.

The move came after Docon Technologies, the promoter entity of API Holdings, sold nearly 1.58 crore shares in Thyrocare, amounting to a 9.9 percent stake. This transaction generated enough funds to help extinguish the group’s term loan liabilities and triggered the removal of pledges on the remaining Thyrocare shares. Importantly, API Holdings has managed to retain majority control of Thyrocare by owning a 51.02 percent stake through Docon Technologies, with the entire residual holding now unencumbered.

“This is not just about becoming debt-free,” said Alok Kumar Jagnani, Group CFO of API Holdings, emphasizing that the company managed to strengthen its balance sheet without allowing Thyrocare ownership to dip below the important 51 percent threshold. The development marks a significant milestone for API Holdings, which had been forced to put its potential initial public offering (IPO) on hold to focus on a financial turnaround.

Thyrocare’s performance since API Holdings acquired it in 2021 has also provided a boost to the group’s overall results. Vice Chairman Siddharth Shah highlighted that shareholders who chose not to participate in the company’s open offer for Thyrocare shares at a bonus-adjusted price of Rs 433 in July 2021 have seen total returns of approximately 51 percent, including dividends. This performance outpaced the Nifty 50 index, which delivered around 41 percent over the same period. Shah noted that these gains underscore the turnaround that many market watchers did not anticipate at the time of the acquisition.

The debt repayment and strengthened ownership position could help shift the narrative around API Holdings from one of financial survival to renewed growth ambitions. API Holdings CEO Rahul Guha described the achievement as the result of operational execution rather than financial engineering, pointing to sustained business performance across Thyrocare and other group units as the driver behind its ability to clear all borrowings.

With the company’s business segments reportedly moving closer to profitability, API Holdings appears poised to focus on margins and cash generation in the period ahead. The group’s debt-free status, combined with an unencumbered controlling stake in Thyrocare, potentially sets the stage for a shift away from balance-sheet repair and towards new growth opportunities in India’s evolving healthcare sector.